必贝特过会两年半获批文：仅1款产品获批上市，70岁董事长钱长庚为美国国籍

Core Viewpoint - The IPO registration of Guangzhou Bibet Pharmaceutical Co., Ltd. has been effective, marking a significant milestone for the company after a lengthy approval process [1][3]. Company Overview - Bibet was established in January 2012 and focuses on innovative drug development, particularly in the fields of oncology, autoimmune diseases, and metabolic diseases [3]. - The company has one product, BEBT-908, which has received conditional approval for marketing by the CDE and is currently in the commercialization phase [3]. Financial Performance - Bibet has not generated revenue or achieved profitability from 2022 to 2024, with net losses of 188 million yuan, 173 million yuan, and 56 million yuan respectively, indicating a narrowing loss trend [3]. - Total assets as of December 31, 2023, were 441.87 million yuan, with a projected decrease to 332.48 million yuan by December 31, 2024 [4]. - The company's equity attributable to shareholders is expected to decrease from 318.12 million yuan in 2023 to 290.22 million yuan in 2024 [4]. Shareholding Structure - The actual controller of Bibet is Qian Changgeng, who holds 15.28% of the shares directly and controls an additional 8.59% through a partnership [5]. - Qian Changgeng, along with other shareholders, has an agreement to act in concert, allowing him to control a total of 43.96% of the company’s shares [5]. Leadership Background - Qian Changgeng, born in 1955, holds a Ph.D. in pharmacology and has extensive experience in the pharmaceutical industry, having held various senior positions in multiple companies [6][7].